Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

SLRN ACELYRIN Inc

3,18

0,03 (0,95%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:30:00

Verzögert um 15 Minuten

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more ACELYRIN Charts.

ACELYRIN (NASDAQ:SLRN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more ACELYRIN Charts.

News ACELYRIN Inc

Form 8-K - Current report
Dienstag 10 Dezember 2024 (2 Wochen vor) • Edgar (US Regulatory)

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Dienstag 10 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Mittwoch 13 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 13 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 13 November 2024 (1 Monat vor) • Edgar (US Regulatory)

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Mittwoch 13 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 8 November 2024 (1 Monat vor) • Edgar (US Regulatory)

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
Mittwoch 6 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K/A - Current report: [Amend]
Montag 4 November 2024 (2 Monate vor) • Edgar (US Regulatory)

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
Mittwoch 16 Oktober 2024 (2 Monate vor) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
Donnerstag 19 September 2024 (3 Monate vor) • GlobeNewswire Inc.

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Sur
Dienstag 10 September 2024 (3 Monate vor) • GlobeNewswire Inc.

Weitere ACELYRIN Inc News-Artikel

Deutsche Telekom (QX)

Invesco QQQ Trust Series 1

Financial Select Sector

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen